Leap Therapeutics Surpasses Forecasts with Strong GAAP EPS Results
Monday, 18 March 2024, 11:10
Leap Therapeutics Exceeds Expectations
In an exciting update for investors, Leap Therapeutics has reported a surprising positive GAAP EPS of -$0.46, exceeding market forecasts by $0.10. This unexpected performance is likely to have a significant impact on the company's trajectory in the near future.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.